Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 11 studies | 50% ± 20% | |
type I pneumocyte | 9 studies | 31% ± 11% | |
hepatocyte | 5 studies | 62% ± 25% | |
endothelial cell | 3 studies | 23% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 39% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 43198.50 | 226 / 226 | 97% | 1140.44 | 392 / 406 |
lung | 99% | 5191.27 | 572 / 578 | 66% | 168.81 | 761 / 1155 |
pancreas | 97% | 623.44 | 319 / 328 | 52% | 24.29 | 92 / 178 |
ovary | 93% | 97.91 | 168 / 180 | 4% | 0.84 | 17 / 430 |
intestine | 42% | 61.38 | 404 / 966 | 33% | 11.35 | 173 / 527 |
spleen | 73% | 140.78 | 176 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 69% | 315.11 | 638 / 929 | 0% | 0 | 0 / 0 |
stomach | 29% | 37.37 | 104 / 359 | 28% | 9.23 | 80 / 286 |
breast | 52% | 268.48 | 238 / 459 | 3% | 3.41 | 32 / 1118 |
adrenal gland | 40% | 67.72 | 102 / 258 | 4% | 5.34 | 10 / 230 |
uterus | 28% | 52.59 | 47 / 170 | 12% | 16.73 | 55 / 459 |
kidney | 35% | 39.20 | 31 / 89 | 3% | 2.25 | 29 / 901 |
prostate | 28% | 16.15 | 69 / 245 | 0% | 0 | 0 / 502 |
bladder | 14% | 3.90 | 3 / 21 | 13% | 25.24 | 66 / 504 |
esophagus | 8% | 4.28 | 117 / 1445 | 16% | 8.52 | 29 / 183 |
adipose | 21% | 65.07 | 253 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 11% | 8.93 | 151 / 1335 | 0% | 0 | 0 / 0 |
heart | 8% | 7.66 | 70 / 861 | 0% | 0 | 0 / 0 |
thymus | 6% | 2.94 | 41 / 653 | 0% | 0.07 | 3 / 605 |
brain | 5% | 1.79 | 135 / 2642 | 1% | 0.41 | 7 / 705 |
skin | 4% | 3.66 | 70 / 1809 | 1% | 0.46 | 5 / 472 |
muscle | 2% | 0.67 | 16 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0002456 | Biological process | T cell mediated immunity |
GO_0006958 | Biological process | complement activation, classical pathway |
GO_0009609 | Biological process | response to symbiotic bacterium |
GO_1903027 | Biological process | regulation of opsonization |
GO_0045959 | Biological process | negative regulation of complement activation, classical pathway |
GO_0045087 | Biological process | innate immune response |
GO_0005615 | Cellular component | extracellular space |
GO_0072562 | Cellular component | blood microparticle |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | C4BPA |
Protein name | C4b-binding protein alpha chain (C4bp) (Proline-rich protein) (PRP) Complement component 4 binding protein alpha |
Synonyms | C4BP |
Description | FUNCTION: Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component. |
Accessions | A6PVY5 ENST00000424088.1 P04003 ENST00000421786.5 F2Z2V7 ENST00000367070.8 |